Breaks Categories: News

TuesdayApr 20, 2021 9:34 am

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Collects 2b Disease Trial Data; Receives NASDAQ Notice Regarding Annual Report

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced collection of all patient data for its phase 2b Dupuytren’s disease trial, which was sponsored by the University of Oxford. The double-blind placebo-controlled trial involved 181 patients who were randomized across three sites, two in the United Kingdom and one in the Netherlands. While follow-up on the trial has been delayed by the COVID-19 pandemic, the company is now analyzing the information and has plans to announce top-line data in an upcoming…

Continue Reading

MondayApr 19, 2021 3:06 pm

BioMedNewsBreaks – GT Biopharma (NASDAQ: GTBP) Releases Q4, Year-End Results, Company Update

GT Biopharma (NASDAQ: GTBP), a clinical-stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (“NK”) cell engager, TriKE(TM) protein biologic technology platform, has released fourth-quarter and year-end financial and company results for the period ended Dec. 31, 2020. Company highlights noted in the announcement included entering into a GMP manufacturing partnership with Cytovance; the initiation of manufacturing of additional solid tumor TriKE for lung, breast, ovarian and gastrointestinal cancer programs in preparation for FDA clinical trials; and enhancing and expanding the company’s board of directors. In addition, the company completed a successful listing on NASDAQ…

Continue Reading

MondayApr 19, 2021 12:59 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces FY2020 Business, Financial Results

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has released its 2020 financial results and has filed its annual report for the fiscal year ended Dec. 31, 2020. Company highlights include bringing the production of NeuroCaps(TM) to the United States; launching the commercial roll-out of its NeuroEEG(TM) and NeuroCap(TM) on a limited basis in the United States market; establishing wholly owned subsidiaries in Russia and Poland; and a significant increase in research and development efforts. Furthermore, the company announced that it has filed a provisional patent application for a new long-term monitoring EEG cap; in addition, its proprietary NeuroCap is…

Continue Reading

ThursdayApr 15, 2021 12:09 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Shareholder Letter Outlines Program Highlights, Provides Business Update

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has shared a letter to shareholders from chair, president and CEO James Sapirstein. The letter noted that AZRX is on track to launch its niclosamide programs in the clinic, noting that just this month the company announced the initiation of RESERVOIR, its Phase 2 clinical trial of niclosamide for the treatment of COVID-19-related gastrointestinal infections; the company also established an agreement with PPD Inc. (“PPD”), a leading clinical research organization, to manage the upcoming Phase 1b/2a ICI-AC trial, planned for Q2…

Continue Reading

WednesdayApr 14, 2021 1:00 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Colleague Receives 2021 International Dupuytren Award

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has received the International Dupuytren Award 2021 for Basic Research. Williams’s research is sponsored by 180 Life Sciences. The award was given for research conducted by and a paper written by Williams. The paper, which was published in “Proceedings of the National Academy of Science, USA,” was titled "Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.” The research identified the collagen VI…

Continue Reading

WednesdayApr 14, 2021 12:49 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Appoints Widely Acclaimed Leader as New Medical Director of Clinical Education

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), today announced the appointment of Mimi Guarneri, MD, FACC as an independent consultant serving in the role of medical director of Clinical Education, effective April 1, 2021. Dr. Guarneri is widely acclaimed as a leading Integrative cardiologist in America and is board-certified in cardiovascular disease, nuclear cardiology and internal and integrative holistic medicine. “We are very excited to welcome Dr. Guarneri to Vivos Therapeutics in this new capacity,” said Kirk Huntsman, Vivos’ chairman…

Continue Reading

WednesdayApr 14, 2021 10:54 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSX.V: LXG) (OTCQB: LXXGF) to Host Private Seminar to Present MiQLab Data from Recent Study

LexaGene Holdings (TSX.V: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, announced that it will host a private event featuring Dr. Shelley Rankin, a professor of microbiology at the University of Pennsylvania’s School of Veterinary Medicine (Penn Vet). Attended by a select group of veterinarians, the private seminar will feature data compiled by Rankin based on her studies evaluating the use of LexaGene’s MiQLab to detect Staphylococcus in specimens gathered from canine skin infections. The event will also include information regarding the use of molecular diagnostics in veterinary medicine as well as analytical and…

Continue Reading

TuesdayApr 13, 2021 2:30 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters Agreement for Upcoming Phase 1b/2a Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, nonsystemic therapies for gastrointestinal (“GI”) diseases, has entered into an agreement with PPD Inc. (NASDAQ: PPD) for its upcoming phase 1b/2a clinical trial. PPD, a leading global contract research organization will manage the clinical trial using both oral immediate-release tablet and topical rectal enema foam formulations of micronized oral niclosamide, or FW-420 (“CRO”). The trial is designed to evaluate proprietary formulations of micronized niclosamide for grade 1 colitis and diarrhea in oncology patients receiving treatment with immune checkpoint inhibitors (“ICIs”). This is the second clinical trial involving niclosamide that the…

Continue Reading

MondayApr 12, 2021 2:48 pm

BioMedNewsBreaks – InvestorBrandNetwork and BioMedWire Collaborate to Deliver Incredible Visibility and Reach for DGE’s Upcoming 2021 Events

InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting companies to the investment community through 50+ brands, today announced that it will partner with Dynamic Global Events (“DGE”) as an official media partner for upcoming events in 2021. In addition, BioMedWire (“BMW”), a specialized communications platform for the life sciences sector and one of the 50+ brands of the InvestorBrandNetwork, will also serve as an official media partner for DGE’s upcoming events. InvestorBrandNetwork and BioMedWire will provide dedicated virtual coverage, including a syndicated article on each event with full dissemination to IBN’s 5000+ strategic syndication partners, social media coverage of…

Continue Reading

MondayApr 12, 2021 12:14 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Presentation of Positive REQORSA(TM) Preclinical Data to Audience of World’s Leading Cancer Researchers

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its collaborators presented positive preclinical data for TUSC2 immunogene therapy (REQORSA(TM)) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (“NSCLC”). According to the update, collaborators also presented positive preclinical data for the use of REQORSA in combination with targeted therapies for the treatment of NSCLC. The data were presented at the 2021 American Association of Cancer Research (“AACR”) annual meeting. “We are pleased to have these positive data that provide further support…

Continue Reading